Ultragenyx Pharmaceutical Inc. (RARE)

Check out top investors' recommendation for RARE
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Eric Schmidt Cowen And Company Buy   Nov 02, '17       Nov 02, '18  N/A 
David Nierengarten Wedbush Securities Inc. Buy   Sep 14, '17       Sep 14, '18  N/A 
Cory Kasimov JPMorgan Buy   Aug 23, '17     76.00  Aug 23, '18  N/A 
Joseph Schwartz Leerink Swann Llc Buy   Aug 23, '17     83.00  Aug 23, '18  N/A 
Eric Schmidt Cowen And Company Buy   Aug 22, '17       Aug 22, '18  N/A 
Eric Schmidt Cowen And Company Buy   Jun 29, '17       Jun 29, '18  N/A 
Cory Kasimov JPMorgan Buy   Feb 25, '16   60.85  110.00  Feb 25, '17  27.31% 
Joseph Schwartz Leerink Swann Llc Buy   Feb 19, '16   63.27  80.00  Feb 19, '17  26.44% 
Carol Werther Summer Street Research Buy   Feb 09, '16   51.64  104.00  Feb 09, '17  38.23% 
Cory Kasimov JPMorgan Buy   Jan 12, '16   86.51    Jan 12, '17  N/A 
Cory Kasimov JPMorgan Buy   Dec 03, '15   95.89  119.00  Dec 03, '16  -22.25% 
Ryan Martins Lazard Capital Markets Buy   Oct 23, '15   96.95  108.00  Oct 23, '16  11.40% 
Eric Schmidt Cowen And Company Buy   Oct 13, '15   82.49    Oct 13, '16  -20.58% 
Liisa Bayko JMP Securities Buy   Jul 09, '15   112.65    Jul 09, '16  -52.64% 
Ryan Martins Lazard Capital Markets Buy   Mar 25, '15   56.63    Mar 25, '16  4.22%